BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Reaffirmed by Needham & Company LLC

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $12.00 target price on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 135.29% from the stock’s previous close.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $5.10 on Wednesday. BioCryst Pharmaceuticals has a 52-week low of $4.45 and a 52-week high of $9.06. The company has a 50-day simple moving average of $5.30 and a 200 day simple moving average of $5.71. The company has a market capitalization of $1.05 billion, a PE ratio of -4.32 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $93.40 million for the quarter, compared to analyst estimates of $89.19 million. As a group, analysts forecast that BioCryst Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in BCRX. Fairfield Bush & CO. purchased a new position in shares of BioCryst Pharmaceuticals in the first quarter worth about $34,000. State of Wyoming purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $35,000. Fifth Third Bancorp boosted its position in shares of BioCryst Pharmaceuticals by 17,500.0% in the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,500 shares during the period. Lazard Asset Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $57,000. Finally, Advisory Services Network LLC boosted its position in shares of BioCryst Pharmaceuticals by 46.3% in the first quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 1,500 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.